A review of acitretin, a systemic retinoid for the treatment of psoriasis

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 10, 2005, Pages 1725-1734

  Lee, Chai Sue ^a   Koo, John ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acitretin; Psoriasis; Retionoids

Indexed keywords

ADALIMUMAB; ALEFACEPT; CALCIPOTRIOL; CHOLESTEROL; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; ETRETIN; ETRETINATE; FUMARIC ACID ETHYL ESTER; INFLIXIMAB; ISOTRETINOIN; METHOTREXATE; PIMECROLIMUS; PLACEBO; PSORALEN; RETINOID DERIVATIVE; SORITANE; TAZAROTENE; TRIACYLGLYCEROL;

ARTHRALGIA; BONE DISEASE; BONE MARROW DISEASE; BRAIN PSEUDOTUMOR; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEILITIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEMYELINATING NEUROPATHY; DERMATITIS; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; FLUSHING; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; HAIR LOSS; HEMATOLOGIC DISEASE; HEPATITIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPEROSTOSIS; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNE DEFICIENCY; INFECTION; KIDNEY DISEASE; LIVER CIRRHOSIS; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FIBROSIS; LONG TERM CARE; LUPUS VULGARIS; LYMPHOCYTOPENIA; MEDICAL DECISION MAKING; MELANOMA; MENTAL DISEASE; META ANALYSIS; MONOTHERAPY; MYALGIA; NAIL DISEASE; PHOTOTHERAPY; PSORIASIS; PSORIASIS VULGARIS; PUSTULAR PSORIASIS; PUSTULOSIS PALMOPLANTARIS; PUVA; PYOGENIC GRANULOMA; RECEPTOR UPREGULATION; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TERATOGENICITY; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

ACITRETIN; ANIMALS; DRUG THERAPY, COMBINATION; HUMANS; PHOTOTHERAPY; PSORIASIS; RETINOIDS;

EID: 23844492927     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.10.1725     Document Type: Review

References (74)

1. KOO J: Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol. Clin. (1996) 14(3):485-496.
2. LEBWOHL M, MENTER A, KOO J, FELDMAN SR: Case studies in severe psoriasis: A clinical strategy. J. Dermatol. Treat. (2003) 14(Suppl. 2):26-46.
3. RAPP S, FELDMAN S, LYN EXUM M, FLEISCHER A, REBOUSSIN D: Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol. (1999) 41(3):401-407.
4. FINLAY A, KHAN G, LUSCOMBE D, SALEK M: Validation of sickness impact profile and psoriasis disability index in psoriasis. Br. J. Dermatol. (1990) 123:751-756.
5. VAN WEELDEN H, VAN DER LEUN JC: Improving the effectiveness of phototherapy for psoriasis. Br. J. Dermatol. (1984) 111:484.
6. VAN WEELDEN H, BAART DE LA FAILLE H, YOUNG E, VAN DER LEUN JC: A new development in UVB phototherapy of psoriasis. Br. J. Dermatol. (1988) 119:11-19.
7. COVEN TR, BURACK LH, GILLEAUDEAU P, KEOGH M, OZAWA M, KRUEGER JG: Narrowband UVB produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UVB. Arch. Dermatol. (1997) 133:1514-1522.
8. KARVONEN J, KOKKONEN EL, RUOTSALAINEN E: 311 nm UVB lamps in the treatment of psoriasis with the Ingram regimen. Acta Derm. Venereol. (Stockh) (1989) 69:82-85.
9. PICOT E, MEUNIER L, PICOT-DEBEZE MC. Treatment of psoriasis with a 311-nm UVB lamp. Br. J. Dermatol. (1992) 127:509-512.
10. STERN RS, LAIRD N: The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study. Cancer (1994) 73(11):2759-2764.
11. STERN RS, NICHOLS KT, VAKEVA LH: Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-up Study. N. Engl. J. Med. (1997) 336(15):1041-1045.
12. ORMEROD AD, MROWIETZ U: Fumaric acid esters, their place in the treatment of psoriasis. Br. J. Dermatol. (2004) 150:630-632.
13. RAPPERSBERGER K, KOMAR M, EBELIN ME et al.: Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J. Invest. Dermatol. (2002) 119(4):876-887.
14. GRIFFITHS C, DUBERTRET L, GOTTLIEB A. Treatment with oral pimecrolimus significantly improves psoriasis with a clear dose-response effect [abstract]. J. Invest. Dermatol. (2003) 121:301.
15. HANIFIN J, FLEMING C, KORMAN N, REITAMO S: Treatment with oral pimecrolimus significantly improves atopic dermatitis (AD) with a clear dose-response effect [abstract]. J. Invest. Dermatol. (2003) 121:1240.
16. BRINDLEY CJ: An overview of recent clinical pharmacokinetic studies with acitretin (Ro-1670, etretin). Dermatologica (1989) 178(2):79-87.
17. DI GIOVANNA JJ, ZECH LA, RUDDEL ME et al.: Etretinate. Persistent serum levels after long-term therapy. Arch. Dermatol. (1989) 125(2):246-251.
18. Soriatane prescribing information. Roche Laboratories, Nutley, NJ, USA (1997)
19. WIEGAND UW. CHOU RC: Pharmacokinetics of acitretin and etretinate. J. Am. Acad. Dermatol. (1998) 39(2 Pt 3):S25-S33.
20. JENSEN BK, CHAWS CL, HUSELTON CA: Clinical evidence that acitretin is esterified to etretinate when administrated with ethanol [Abstract]. FASEB J. (1992) 6:A1570.
21. LARSEN FG, JAKOBSEN P, KNUDSEN J, WEISMANN K, KRAGBALLE K, NIELSEN KUDSK F: Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J. Invest. Dermatol. (1993) 100: 623-627.
22. PILKINGTON T, BROGDEN RN: Acitretin: a review of its pharmacology and therapeutic use. Drugs (1992) 43(4):597-627.
23. CHANDRARATNA RA: Rational design of receptor-selective retinoids. J. Am. Acad. Dermatol. (1998) 39:S124-S128.
24. KANG S, LI SY. VOORHEES JJ: Pharmacology and molecular action of retinoids and vitamin D in skin. J. Invest. Dermatol. Symposium Proc. (1996) 1:15-21.
25. ROWE A: Retinoids X receptors. Int. J. Biochem. Cell Biol. (1997) 29:276-278.
26. YAMAUCHI PS, RIZK D, KORMILI T, PATNAIK R, LOWE NJ: Systemic Retinoids. In: Therapy of Moderate-to-Severe Psoriasis. GD Weinstein, AB Gottlieb (Eds), Marcel Dekker, Inc, New York, NY, USA (2003)137-150.
27. CHAMBON P: The retinoid signaling pathway: molecular and genetic analysis. Semin. Cell Biol. (1994) 5:115-125.
28. SAURAT JH: Retinoids and psoriasis: novel issues in retinoid pharmacology and implications for psoriasis treatment. J. Am. Acad. Dermatol. (1999) 41:S2-S6.
29. APFEL C, CRETTAZ M, SIEGENTALER G, HUNZIKER W: Synthetic retinoids: binding to retinoic acid receptors. In: Retinoids 10 Years On. JH Saurat (Ed.), Korgen, Basel, Switzerland (1991).
30. MCCLURE SL, VALENTINE J, GORDON KB: Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Saf. (2002) 25:913-927.
31. LAUGIER JP, DE SOUSA G, BUN H, GEIGER JM, SURBER C, RAHMANI R: Acitretin biotransformation into etretinate: role of ethanol on in vitro hepatic metabolism. Dermatology (1994) 188:122-125.
32. GEIGER JM, SAURAT JH: Acitretin and etretinate. How and when they should be used. Dermatol. Clin. (1993) 11:117-129.
33. MCNAMARA PJ, JEWELL RC, JENSEN BK, BRINDLEY CJ: Food increases the bioavailability of acitretin. J. Clin. Pharmacol. (1988) 28:1051-1055.
34. LING MR: Acitretin: optimal dosing strategies. J. Am. Acad. Dermatol. (1999) 41(3):S2-S6.
35. LOWE NJ, LAZARUS V, MATT L: Systemic retinoid therapy for psoriasis. J. Am. Acad. Dermatol. (1988) 19:186-191.
36. GOLDFARB MT, ELLIS CN, GUPTA AK, TINCOFF T, HAMILTON TA, VOORHEES JJ: Acitretin improved psoriasis in a dose-dependent fashion. J. Am. Acad. Dermatol. (1988) 18:655-662.
37. OLSEN EA, WEED WW, MEYER CJ, COBO LM: A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis. J. Am. Acad. Dermatol. (1989) 21:681-686.
38. TOROL L, KADAR L, GEIGER JM: Acitretin treatment of severe psoriasis. Acta. Dermatol. Venereol. Suppl. (1989) 146:104-106.
39. MURRAY HE, ANHALT AW, LESSARD R et al.: A 12-month treatment of severe psoriasis with acitretin: results of a Candadian open multicenter trial. J. Am. Acad. Dermatol. (1991) 24:598-602.
40. GEIGER JM, CZARNETSKI BM: Acitretin (Ro 10-1670, etretin): overall evaluation of clinical studies. Deramtologica (1988) 176:182-190.
41. LASSUS A, GEIGER JM, NYBLOM M, VIRRANKOSKI T, KAARTAMAA M, INGERVO L: Treatment of severe psoriasis with etretin (Ro 10-1670). Br. J. Dermaol. (1987) 117:333-341.
42. OZAWA A, OHKIDO M, HARUKI Y et al.: Treatment of generalized pustular psoriasis: a multicenter study in Japan. J. Dermatol. (1999) 26:141-149.
43. KOO J: Sequential therapy of psoriasis. Introducing a new therapeutic paradigm for better clinical results. J. Am. Acad. Dermatol. (1999) 41:S25-S28.
44. WOLVERTON SE, NGUYEN EQ: Systemic retinoids. In: Comprehensive Dermatologic Drug Therapy. SE Wolverton (Ed.), WB Saunders Company, Philadelphia, PA, USA (2001):269-310.
45. BUCCHERI L, KATCHEN BR, KARTER AJ et al.: Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch. Dermatol. (1997) 133:711-715.
46. VAN DE KERKHOF PC, CAMBAZARD F, HUTCHINSON PE et al.: The effect of addition of calcipotriol ointment to acitretin therapy in psoriasis. Br. J. Dermatol. (1998) 138:84-89.
47. GIANNETTI A, COPPINI M, BERTAZZONI MG et al.: Clinical trial of the efficacy and safety of oral etretinate with calcipotriol cream compared with etretinate alone in moderate-severe psoriasis. J. Eur. Acad. Dermatol. Venereol. (1999) 13:91-95.
48. RIM JH, PARK JY, CHOE YB, YOUN JI: The efficacy of calcipotriol + acitretin combination therapy for psoriasis. Am. J. Clin. Dermatol. (2003) 4(7):507-510.
49. TANEW A, GUGGENBICHLER A, HONIGSMANN H, GEIGER JM, FRITSCH P: Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J. Am. Acad. Dermatol. (1991) 26:682-684.
50. SAURAT JH, GEIGER JM, AMBLARD P, et al.: Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA, and placebo-PUVA in the treatment of severe psoriasis. Dermatologica (1988) 177:218-224.
51. LAURAHANTA J, GEIGER JM: A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis. Br. J. Dermatol. (1989) 121:107-112.
52. LINDELOF B, SIGURGEIRSSON B, TEGNER E et al.: PUVA and cancer: a large-scale epidemiologic study. Lancet (1991) 338:91-93.
53. VAN DE KERKHOF PC, DE ROOIJ MJ: Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporin treatment: response to long-term acitretin maintenance. Br. J. Dermatol. (1997) 136:275-278.
54. BAVINCK JN, TIEBEN LM, VAN DER WOUDE FJ et al.: Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J. Clin. Oncol. (1995) 13:1933-1938.
55. YUAN ZF, DAVID A, MACDONALD K et al.: Use of acitretin for the skin complications in renal transplant recipients. N. Z. Med. J. (1995) 108:255-256.
56. MCKENNA DB, MURPHY GM: Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br. J. Dermatol. (1999) 140:656-660.
57. MCNAMARA IR, MUIR J, GALBRAITH AJ: Acitretin for prophylaxis of cutaneous malignancies after cardiac transplantation. J. Heart Lung Transplant (2002) 21:1201-1205.
58. MUCHENBERGER S, SCHOF E, SIMON JC: The combination of oral acitretin and bath PUVA for the treatment of severe psoriasis. Br. J. Dermatol. (1997) 137:587-589.
59. RUZICKA T, SOMMERBURG C, BRAUN-FALCO O et al.: Efficency of acitretin in combination with UV-B in the treatment of severe psoriasis. Arch. Dermatol. (1990) 126:482-486.
60. LOWE N, PRYSTOWSKY JH, BOURGET T, EDELSTEIN J, NYCHAY S, ARMSTRONG R: Acitretin plus UVB therapy for psoriasis: comparisons with placebo plus UVB and acitretin alone. J. Am. Acad. Dermatol. (1991) 24:591-594.
61. IEST J, BOER J: Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. Br. J. Dermatol. (1989) 120:665-670.
62. LEBWOHL M: Acitretin in combination with UVB or PUVA. J. Am. Acad. Dermatol. (1999) 41(3 Pt 2):S22-S24.
63. PULS PI, ROZENBLIT, LEBWOHL M: Retrospective study of the efficacy of narrowband UVB and acitretin. J. Dermatol. Treat.(2003) 14(Suppl. 2):17-20.
64. Soriatane prescribing information. Connetics Corporation, Palo Alto, CA, USA (2004).
65. IYER S, YAMAUCHI P, LOWE NJ: Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br. J. Dermatol. (2002) 146:118-121.
66. DAVID M, HODAK E, LOWE NJ: Adverse effects of retinoids. Med. Toxicol. (1988) 3:273-288.
67. KATZ HI, WAALEN J, LEACH EE: Acitretin in psoriasis: An overview of adverse effects. J. Am. Acad. Dermatol. (1999) 41(3 Pt 2):S7-S12.
68. KOO J, NGUYEN Q, GAMBLA C: Advances in psoriasis therapy. Adv. Dermatol. (1997) 12:47-72.
69. WOLVERTON SE: Retinoids. In: Systemic Drugs for Skin Diseases. SE Wolverton, JK Wilkins (Eds), WB Saunders, Philadelphia, PA, USA (1991):187-218.
70. LEE E, KOO J: Single-center retrospective study of long-term use of low-dose acitretin (Soriatane®) for psoriasis. J. Dermatol. Treat. (2004) 15:8-13.
71. VAHLQUIST C, OLSSON AG, LINDHOLM A, VAHLQUIST A: Effects of gemfibrozil (Lopid) on hyperlipidemia in acitretin-treated patients. Results of a double-blind cross-over study. Acta. Derm. Venereol. (1995) 75:377-380.
72. SCANDANAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383-1389.
73. ROENIGK HH Jr, CALLEN JP. GUZZO CA et al.: Effects of acitretin on the liver. Obstet. Gynecol. (1999) 41:584-588.
74. STERN RS, FITZGERALD E, ELLIS CN, LOWE N, GOLDFARB MT, BAUGHMAN RD: The safety of etretinate as long-term therapy for psoriasis: results of the etretinate follow-up study. J. Am. Acad. Dermatol. (1995) 33:44-52.